July 2023—OGT, a Sysmex Group company, announced a commercial partnership with Applied Spectral Imaging. The agreement will grant OGT rights to market ASI’s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that the companies say combines the strengths of OGT’s CytoCell FISH portfolio with ASI’s imaging and analysis capabilities.
Read More »OGT expands NGS cancer panel offering
February 2021—Oxford Gene Technology has expanded its SureSeq range of next-generation sequencing panels to include a comprehensive myeloid panel and a breast and ovarian cancer panel that incorporate copy number variation detection.
Read More »OGT expands NGS cancer panel offering
Nov. 6, 2020—Oxford Gene Technology has expanded its SureSeq range of next-generation sequencing panels to include a comprehensive myeloid panel and a breast and ovarian cancer panel that incorporate copy number variation detection.
Read More »OGT’s CytoSure v3 improves reporting rate
October 2020—According to a recent NPJ Genomic Medicine paper (Jezkova J, et al. 2020;5:28), Oxford Gene Technology’s CytoSure Constitutional v3 array design significantly improved reporting rate and proved to be a powerful tool for the detection of small pathogenic intragenic deletions and duplications in developmental disorder research. The paper was led by a consortium of National Health Service genomic medicine centers in the U.K.; it compared the enhanced exon-level gene coverage of the v3 array with a conventional array design.
Read More »Cytocell portfolio now in China, Spain
September 2020—Oxford Gene Technology, a Sysmex Group company, announced that Sysmex sales and support services are now available in China and Spain for Cytocell customers. The expansion involves Sysmex Shanghai, Sysmex Hong Kong, and Sysmex Espana.
Read More »OGT’s CytoSure v3 improves reporting rate
July 27, 2020—In a recent NPJ Genomic Medicine paper, Oxford Gene Technology’s CytoSure Constitutional v3 array design has been shown to significantly improve reporting rate and been proven as a powerful tool for detection of small pathogenic intragenic deletions and duplications in developmental disorder research.
Read More »OGT expands SureSeq NGS portfolio
April 13, 2020—Oxford Gene Technology has added detection capabilities for translocations and difficult-to-sequence partial tandem duplications in its MyPanel customizable SureSeq NGS panels.
Read More »OGT launches NGS panel for chronic lymphocytic leukemia
March 2020—Oxford Gene Technology launched its SureSeq CLL + CNV Panel, a next-generation sequencing panel designed to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia progression.
Read More »CytoSure constitutional NGS panel
January 2020—Oxford Gene Technology has developed the CytoSure NGS panel for the detection of loss of heterozygosity, mosaicism, copy number variants, single nucleotide variants, and indels. The solution features up-to-date content for intellectual disability and developmental delay, the targeted NGS panel, and Interpret software.
Read More »OGT launches NGS panel for chronic lymphocytic leukemia
Jan. 15, 2020—Oxford Gene Technology launched its SureSeq CLL + CNV Panel, a next-generation sequencing panel designed to detect 12 key genes and five chromosomal regions implicated in chronic lymphocytic leukemia progression.
Read More »OGT releases SureSeq NGS library prep kit
June 19, 2019– Oxford Gene Technology has expanded its SureSeq portfolio with the SureSeq NGS Library Preparation Kit, a library preparation solution for hybridization-based target capture in next-generation sequencing.
Read More »FDA clears FISH probes for AML, MDS
Feb. 11, 2019—Oxford Gene Technology has been granted de novo classification by the FDA for eight Cytocell
Read More »OGT expands sales support in Europe
October 2018—Oxford Gene Technology announced it is selling its Cytocell fluorescence in situ hybridization products through several affiliates of Sysmex Corp. in Europe. “The move is a testament to the ongoing successful integration of the two companies and commitment to combine efforts to support and serve end users,” according to a press release from OGT.
Read More »SureSeq NGS analysis software
September 2018—Oxford Gene Technology launched its SureSeq Interpret software, designed to be used with SureSeq NGS panels, to analyze and visualize a range of mutation types and structural variants. The software rapidly processes sequencing data and delivers accurate mutation calling with 100 percent sensitivity and 99.9 percent specificity at >1 percent variant allele frequency.
Read More »SureSeq NGS analysis software
September 2018—Oxford Gene Technology launched its SureSeq Interpret software, designed to be used with SureSeq NGS panels, to analyze and visualize a range of mutation types and structural variants. The software rapidly processes sequencing data and delivers accurate mutation calling with 100 percent sensitivity and 99.9 percent specificity at >1 percent variant allele frequency.
Read More »Cytocell unveils new website
March 20, 2018—Oxford Gene Technology has redeveloped its Cytocell fluorescence in situ hybridization probes website, www.cytocell.com ...
Read More »NGS cancer panels, 6/17
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
Read More »FISH probes, 9/16
September 2016—Oxford Gene Technology has expanded its catalog of fluorescence in situ hybridization products with nine Cytocell Aquarius probes: ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua, and Chromosome 15 Alpha Satellite Probe Red.
Read More »FFPE DNA repair kit, 7/16
July 2016—Oxford Gene Technology introduced its SureSeq FFPE DNA Repair Mix for repairing a broad range of damage in formalin-fixed, paraffin-embedded–derived DNA.
Read More »FISH probes for glial tumors, 6/16
June 2016—Oxford Gene Technology launched its CE-IVD labeled Cytocell Aquarius 1p36/1q25 and 19q13/19p13 Deletion Probe Kit, a fluorescence in situ hybridization kit for the reliable investigation of glial tumors.
Read More »OGT licenses SNP probe technology, 12/15
December 2015—Oxford Gene Technology has entered into a deal with Baylor Miraca Genetics Laboratories, licensing the use of OGT’s proprietary single nucleotide polymorphism array probe technology.
Read More »